Ewha Med J.  2023 Dec;46(S1):e32. 10.12771/emj.2023.e32.

Management of Hyperphagia and Obesity in Prader–Willi Syndrome

• Hwang J
• Cho SY

• KMID: 2550852
• DOI: http://doi.org/10.12771/emj.2023.e32

Abstract

Prader-Willi syndrome (PWS) is a neurodevelopmental disorder caused by the absence of paternally expressed imprinted genes on chromosome 15q11–13. Individuals with PWS typically experience feeding difficulties and a lack of appetite in infancy, followed by weight gain, uncontrolled appetite, and a lack of satiety. Hyperphagia in PWS is exacerbated by impaired satiety, low energy expenditure, and intellectual difficulties, including obsessive-compulsive disorder and/or autistic behaviors. Without rigorous external management of their eating behaviors, patients with PWS become severely obese and are at a higher risk of obesity-related morbidities, such as type 2 diabetes, obstructive sleep apnea, and hypertension. Moreover, the main causes of death for PWS are obesity-related comorbidities, such as renal failure, pulmonary embolism, and respiratory and heart failure. Clinical experiences with different supplements, diets, and other methods have not been encouraging. However, therapeutic options for patients with PWS may be improving, based on recent clinical trials for a number of medications. This report reviews the causes and management of hyperphagia, as well as previous and recent clinical trials aimed at treating hyperplasia in PWS. We are optimistic that the novel treatments currently in development will help alleviate the complex metabolic issues associated with PWS.

Keyword

Appetite; Clinical trial; Hyperphagia

Reference

References

1. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med. 2012; 14(1):10–26. DOI: 10.1038/gim.0b013e31822bead0. PMID: 22237428.

2. Cassidy SB, Driscoll DJ. Prader–Willi syndrome. Eur J Hum Genet. 2009; 17(1):3–13. DOI: 10.1038/ejhg.2008.165. PMID: 18781185. PMCID: PMC2985966.

3. Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, et al. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. Am J Clin Nutr. 2015; 102(4):780–790. DOI: 10.3945/ajcn.115.112581. PMID: 26224300.

4. Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold JA, Kimonis V, et al. Nutritional phases in Prader–Willi syndrome. Am J Med Genet A. 2011; 155(5):1040–1049. DOI: 10.1002/ajmg.a.33951. PMID: 21465655. PMCID: PMC3285445.

5. Gross N, Rabinowitz R, Gross-Tsur V, Hirsch HJ, Eldar-Geva T. Prader–Willi syndrome can be diagnosed prenatally. Am J Med Genet A. 2015; 167(1):80–85. DOI: 10.1002/ajmg.a.36812. PMID: 25338954.

6. Lee J, Isojima T, Chang MS, Kwun YH, Huh R, Cho SY, et al. Disease-specific growth charts for Korean infants with Prader–Willi syndrome. Am J Med Genet A. 2015; 167(1):86–94. DOI: 10.1002/ajmg.a.36816. PMID: 25339260.

7. Rosenbloom ST, Butler MG. Development and implementation of electronic growth charts for infants with Prader–Willi syndrome. Am J Med Genet A. 2012; 158A(11):2743–2749. DOI: 10.1002/ajmg.a.35581. PMID: 22903930. PMCID: PMC6815511.

8. Gantz MG, Andrews SM, Wheeler AC. Food and non-food-related behavior across settings in children with Prader–Willi syndrome. Genes. 2020; 11(2):204. DOI: 10.3390/genes11020204. PMID: 32079283. PMCID: PMC7074075.

9. McAllister CJ, Whittington JE, Holland AJ. Development of the eating behaviour in Prader–Willi syndrome: advances in our understanding. Int J Obes. 2011; 35(2):188–197. DOI: 10.1038/ijo.2010.139. PMID: 20680019.

10. Hedgeman E, Ulrichsen SP, Carter S, Kreher NC, Malobisky KP, Braun MM, et al. Long-term health outcomes in patients with Prader–Willi syndrome: a nationwide cohort study in Denmark. Int J Obes. 2017; 41(10):1531–1538. DOI: 10.1038/ijo.2017.139. PMID: 28634363.

11. Damen L, Donze SH, Kuppens RJ, Bakker NE, De Graaff LCG, van der Velden JA, et al. Three years of growth hormone treatment in young adults with Prader-Willi syndrome: sustained positive effects on body composition. Orphanet J Rare Dis. 2020; 15(1):163. DOI: 10.1186/s13023-020-01440-6. PMID: 32580778. PMCID: PMC7313113.

12. Tan Q, Orsso CE, Deehan EC, Triador L, Field CJ, Tun HM, et al. Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: a narrative review. Obes Rev. 2020; 21(5):e12992. DOI: 10.1111/obr.12992. PMID: 31889409.

13. Kang S, Seo MY, Kim SH, Park MJ. Changes in lifestyle and obesity during the COVID-19 pandemic in Korean adolescents: based on the Korea Youth Risk Behavior Survey 2019 and 2020. Ann Pediatr Endocrinol Metab. 2022; 27(4):281–288. DOI: 10.6065/apem.2142228.114. PMID: 35798306. PMCID: PMC9816461.

14. Manzardo AM, Loker J, Heinemann J, Loker C, Butler MG. Survival trends from the Prader–Willi syndrome Association (USA) 40-year mortality survey. Genet Med. 2018; 20(1):24–30. DOI: 10.1038/gim.2017.92. PMID: 28682308. PMCID: PMC5756527.

15. Grugni G, Crinò A, Bosio L, Corrias A, Cuttini M, De Toni T, et al. The Italian National Survey for Prader–Willi syndrome: an epidemiologic study. Am J Med Genet A. 2008; 146A(7):861–872. DOI: 10.1002/ajmg.a.32133. PMID: 18203198.

16. Butler MG, Manzardo AM, Heinemann J, Loker C, Loker J. Causes of death in Prader-Willi syndrome: Prader-Willi syndrome Association (USA) 40-year mortality survey. Genet Med. 2017; 19(6):635–642. DOI: 10.1038/gim.2016.178. PMID: 27854358. PMCID: PMC5435554.

17. Kim MS, Kim J, Cho J, Cho SY, Jin DK. Tailored management of life-threatening complications related to severe obesity in a young adult with Prader-Willi syndrome. Ann Pediatr Endocrinol Metab. 2022; 27(2):148–152. DOI: 10.6065/apem.2142022.011. PMID: 34670069. PMCID: PMC9260376.

18. Kim M, Kim J. Cardiometabolic risk factors and metabolic syndrome based on severity of obesity in Korean children and adolescents: data from the Korea National Health and Nutrition Examination Survey 2007–2018. Ann Pediatr Endocrinol Metab. 2022; 27(4):289–299. DOI: 10.6065/apem.2142230.115. PMID: 35718891. PMCID: PMC9816464.

19. Laurier V, Lapeyrade A, Copet P, Demeer G, Silvie M, Bieth E, et al. Medical, psychological and social features in a large cohort of adults with Prader–Willi syndrome: experience from a dedicated centre in France. J Intellect Disabil Res. 2015; 59(5):411–421. DOI: 10.1111/jir.12140. PMID: 24947991.

20. Kim JH, Lim JS. The association between C-reactive protein, metabolic syndrome, and prediabetes in Korean children and adolescents. Ann Pediatr Endocrinol Metab. 2022; 27(4):273–280. DOI: 10.6065/apem.2142226.113. PMID: 35798307. PMCID: PMC9816469.

21. Miller JL, Linville TD, Dykens EM. Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study. J Pediatr Endocrinol Metab. 2014; 27((1-2)):23–29. DOI: 10.1515/jpem-2013-0116. PMID: 23893676. PMCID: PMC3864175.

22. Butler MG, Lee PDK, Whitman BY. Management of Prader-Willi syndrome. 3rd ed. New York: Springer;2006. DOI: 10.1007/978-0-387-33536-0.

23. Kim JH, Yoo JH. A national survey of transition from pediatric to adult healthcare providers for adolescents and young adults with type 1 diabetes: perspectives of pediatric endocrinologists in Korea. Ann Pediatr Endocrinol Metab. 2021; 26(2):112–117. DOI: 10.6065/apem.2040194.097. PMID: 33626630. PMCID: PMC8255862.

24. Deal CL, Tony M, Höybye C, Allen DB, Tauber M, Christiansen JS. Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 2013; 98(6):E1072–E1087. DOI: 10.1210/jc.2012-3888. PMID: 23543664. PMCID: PMC3789886.

25. Jørgensen AP, Ueland T, Sode-Carlsen R, Schreiner T, Rabben KF, Farholt S, et al. Glucose homeostasis in adults with Prader–Willi syndrome during treatment with growth hormone: results from a 12-month prospective study. Growth Horm IGF Res. 2014; 24(1):16–21. DOI: 10.1016/j.ghir.2013.11.002. PMID: 24360789.

26. Sipilä I, Sintonen H, Hietanen H, Apajasalo M, Alanne S, Viita AM, et al. Long-term effects of growth hormone therapy on patients with Prader–Willi syndrome. Acta Paediatr. 2010; 99(11):1712–1718. DOI: 10.1111/j.1651-2227.2010.01904.x. PMID: 20545932.

27. Schmidt H, Bechtold-Dalla Pozza S, Bonfig W, Schwarz HP, Dokoupil K. Successful early dietary intervention avoids obesity in patients with Prader-Willi syndrome: a ten-year follow-up. J Pediatr Endocrinol Metab. 2008; 21(7):651–655. DOI: 10.1515/JPEM.2008.21.7.651. PMID: 18780599.

28. Miller JL. Approach to the child with Prader-Willi syndrome. J Clin Endocrinol Metab. 2012; 97(11):3837–3844. DOI: 10.1210/jc.2012-2543. PMID: 23129592. PMCID: PMC3485601.

29. Alsaif M, Elliot SA, MacKenzie ML, Prado CM, Field CJ, Haqq AM. Energy metabolism profile in individuals with Prader-Willi syndrome and implications for clinical management: a systematic review. Adv Nutr. 2017; 8(6):905–915. DOI: 10.3945/an.117.016253. PMID: 29141973. PMCID: PMC5682993.

30. Miller JL, Lynn CH, Shuster J, Driscoll DJ. A reduced-energy intake, well-balanced diet improves weight control in children with Prader-Willi syndrome. J Hum Nutr Diet. 2013; 26(1):2–9. DOI: 10.1111/j.1365-277X.2012.01275.x. PMID: 23078343. PMCID: PMC4112078.

31. Meslier V, Laiola M, Roager HM, De Filippis F, Roume H, Quinquis B, et al. Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake. Gut. 2020; 69(7):1258–1268. DOI: 10.1136/gutjnl-2019-320438. PMID: 32075887. PMCID: PMC7306983.

32. Shields N, Westle A, Bennell KL, Taylor NF. Physiotherapists perceived developing positive rapport facilitates participation in exercise among people with Prader-Willi syndrome: a qualitative study. Disabil Rehabil. 2020; 42(24):3475–3480. DOI: 10.1080/09638288.2019.1597176. PMID: 30971136.

33. Johnson L, Manzardo AM, Miller JL, Driscoll DJ, Butler MG. Elevated plasma oxytocin levels in children with Prader–Willi syndrome compared with healthy unrelated siblings. Am J Med Genet A. 2016; 170(3):594–601. DOI: 10.1002/ajmg.a.37488. PMID: 26615966. PMCID: PMC6679917.

34. Love TM. Oxytocin, motivation and the role of dopamine. Pharmacol Biochem Behav. 2014; 119:49–60. DOI: 10.1016/j.pbb.2013.06.011. PMID: 23850525. PMCID: PMC3877159.

35. Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab. 1995; 80(2):573–579. DOI: 10.1210/jcem.80.2.7852523. PMID: 7852523.

36. Shalma NM, Alsharabasy MA, Taha AM, Alsawareah A, Manirambona E, Ahmed SK, et al. The efficacy of intranasal oxytocin in patients with Prader-Willi syndrome: a systematic review and meta-analysis. Diabetes Metab Syndr. 2023; 17(2):102711. DOI: 10.1016/j.dsx.2023.102711. PMID: 36774885.

37. Dykens EM, Miller J, Angulo M, Roof E, Reidy M, Hatoum HT, et al. Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome. JCI Insight. 2018; 3(12):e98333. DOI: 10.1172/jci.insight.98333. PMID: 29925684. PMCID: PMC6124421.

38. Roof E, Deal CL, McCandless SE, Cowan RL, Miller JL, Hamilton JK, et al. Intranasal carbetocin reduces hyperphagia, anxiousness, and distress in Prader-Willi syndrome: CARE-PWS phase 3 trial. J Clin Endocrinol Metab. 2023; 108(7):1696–1708. DOI: 10.1210/clinem/dgad015. PMID: 36633570. PMCID: PMC10271225.

39. Kimonis V, Surampalli A, Wencel M, Gold JA, Cowen NM. A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome. PLoS One. 2019; 14(9):e0221615. DOI: 10.1371/journal.pone.0221615. PMID: 31545799. PMCID: PMC6756513.

40. Rahman QFA, Jufri NF, Hamid A. Hyperphagia in Prader-Willi syndrome with obesity: from development to pharmacological treatment. Intractable Rare Dis Res. 2023; 12(1):5–12. DOI: 10.5582/irdr.2022.01127. PMID: 36873672. PMCID: PMC9976092.

41. Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, et al. Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2023; 108(7):1676–1685. DOI: 10.1210/clinem/dgad014. PMID: 36639249. PMCID: PMC10271219.

42. van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014; 221(1):T1–T16. DOI: 10.1530/JOE-13-0414. PMID: 24323912.

43. Sze L, Purtell L, Jenkins A, Loughnan G, Smith E, Herzog H, et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2011; 96(8):E1314–E1319. DOI: 10.1210/jc.2011-0038. PMID: 21632815.

44. Arenz T, Schwarzer A, Pfluger T, Koletzko S, Schmidt H. Delayed gastric emptying in patients with Prader Willi syndrome. J Pediatr Endocrinol Metab. 2010; 23(9):867–871. DOI: 10.1515/jpem.2010.140. PMID: 21175084.

45. Collet TH, Dubern B, Mokrosinski J, Connors H, Keogh JM, Mendes De Oliveira E, et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (setmelanotide) in MC4R deficiency. Mol Metab. 2017; 6(10):1321–1329. DOI: 10.1016/j.molmet.2017.06.015. PMID: 29031731. PMCID: PMC5641599.

46. Duis J, Van Wattum PJ, Scheimann A, Salehi P, Brokamp E, Fairbrother L, et al. A multidisciplinary approach to the clinical management of Prader–Willi syndrome. Mol Genet Genomic Med. 2019; 7(3):e514. DOI: 10.1002/mgg3.514. PMID: 30697974. PMCID: PMC6418440.

47. Markham A. Setmelanotide: first approval. Drugs. 2021; 81(3):397–403. DOI: 10.1007/s40265-021-01470-9. PMID: 33638809.

48. Beauloye V, Diene G, Kuppens R, Zech F, Winandy C, Molinas C, et al. High unacylated ghrelin levels support the concept of anorexia in infants with Prader-Willi syndrome. Orphanet J Rare Dis. 2016; 11(1):56. DOI: 10.1186/s13023-016-0440-0. PMID: 27146407. PMCID: PMC4855494.

49. Kuppens RJ, Diène G, Bakker NE, Molinas C, Faye S, Nicolino M, et al. Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader-Willi syndrome. Endocrine. 2015; 50(3):633–642. DOI: 10.1007/s12020-015-0614-x. PMID: 25989955. PMCID: PMC4662713.

50. AdisInsight. A phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an unacylated ghrelin analogue, on food-related behaviors in patients with Prader-Willi syndrome [Internet]. Cham (CH): AdisInsight;c2021. [cited 2023 Sep 3]. Available from: https://adisinsight.springer.com/trials/700299063.

51. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007; 150(5):613–623. DOI: 10.1038/sj.bjp.0707133. PMID: 17245363. PMCID: PMC2189767.

52. Holland A, Manning K. t-VNS to treat disorders of behaviour in Prader-Willi syndrome and in people with other neurodevelopmental conditions. Auton Neurosci. 2022; 239:102955. DOI: 10.1016/j.autneu.2022.102955. PMID: 35219158.

53. Bravo GL, Poje AB, Perissinotti I, Marcondes BF, Villamar MF, Manzardo AM, et al. Transcranial direct current stimulation reduces food-craving and measures of hyperphagia behavior in participants with Prader-Willi syndrome. Am J Med Genet B Neuropsychiatr Genet. 2016; 171(2):266–275. DOI: 10.1002/ajmg.b.32401. PMID: 26590516. PMCID: PMC6668339.

54. Azevedo CC, Trevizol AP, Gomes JS, Akiba H, Franco RR, Simurro PB, et al. Transcranial direct current stimulation for Prader-Willi syndrome. J ECT. 2021; 37(1):58–63. DOI: 10.1097/YCT.0000000000000722. PMID: 33009217.

55. Poje AB, Manzardo A, Gustafson KM, Liao K, Martin LE, Butler MG. Effects of transcranial direct current stimulation (tDCS) on Go/NoGo performance using food and non-food stimuli in patients with Prader-Willi syndrome. Brain Sci. 2021; 11(2):250. DOI: 10.3390/brainsci11020250. PMID: 33671295. PMCID: PMC7922059.

56. Scheimann AO, Butler MG, Gourash L, Cuffari C, Klish W. Critical analysis of bariatric procedures in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr. 2008; 46(1):80–83. DOI: 10.1097/01.mpg.0000304458.30294.31. PMID: 18162838. PMCID: PMC6815229.

57. Vaiani E, Herzovich V, Chaler E, Chertkoff L, Rivarola MA, Torrado M, et al. Thyroid axis dysfunction in patients with Prader-Willi syndrome during the first 2 years of life. Clin Endocrinol. 2010; 73(4):546–550. DOI: 10.1111/j.1365-2265.2010.03840.x. PMID: 20560980.

58. Kweh FA, Miller JL, Sulsona CR, Wasserfall C, Atkinson M, Shuster JJ, et al. Hyperghrelinemia in Prader-Willi syndrome begins in early infancy long before the onset of hyperphagia. Am J Med Genet A. 2015; 167(1):69–79. DOI: 10.1002/ajmg.a.36810. PMID: 25355237. PMCID: PMC4391201.

59. Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab. 2008; 93(11):4183–4197. DOI: 10.1210/jc.2008-0649. PMID: 18697869.

60. Kaar JL, Brinton JT, Crume T, Hamman RF, Glueck DH, Dabelea D. Leptin levels at birth and infant growth: the EPOCH study. J Dev Orig Health Dis. 2014; 5(3):214–218. DOI: 10.1017/S204017441400021X. PMID: 24901661. PMCID: PMC4776652.

61. Haqq AM, Muehlbauer MJ, Newgard CB, Grambow S, Freemark M. The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index. J Clin Endocrinol Metab. 2011; 96(1):E225–E232. DOI: 10.1210/jc.2010-1733. PMID: 20962018. PMCID: PMC3038476.

62. Rigamonti AE, Bini S, Piscitelli F, Lauritano A, Di Marzo V, Vanetti C, et al. Hedonic eating in Prader-Willi syndrome is associated with blunted PYY secretion. Food Nutr Res. 2017; 61(1):1297553. DOI: 10.1080/16546628.2017.1297553. PMID: 28659728. PMCID: PMC5475322.

63. Xu M, Zhang Y, von Deneen KM, Zhu H, Gao JH. Brain structural alterations in obese children with and without Prader-Willi syndrome. Hum Brain Mapp. 2017; 38(8):4228–4238. DOI: 10.1002/hbm.23660. PMID: 28543989. PMCID: PMC6866858.

64. Manzardo AM, Johnson L, Miller JL, Driscoll DJ, Butler MG. Higher plasma orexin a levels in children with Prader–Willi syndrome compared with healthy unrelated sibling controls. Am J Med Genet A. 2016; 170(9):2328–2333. DOI: 10.1002/ajmg.a.37777. PMID: 27518917. PMCID: PMC6697081.

65. Tauber M, Mantoulan C, Copet P, Jauregui J, Demeer G, Diene G, et al. Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients. Orphanet J Rare Dis. 2011; 6:47. DOI: 10.1186/1750-1172-6-47. PMID: 21702900. PMCID: PMC3141367.

66. Einfeld SL, Smith E, McGregor IS, Steinbeck K, Taffe J, Rice LJ, et al. A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome. Am J Med Genet A. 2014; 164(9):2232–2239. DOI: 10.1002/ajmg.a.36653. PMID: 24980612.

67. Kuppens RJ, Donze SH, Hokken-Koelega ACS. Promising effects of oxytocin on social and food-related behaviour in young children with Prader–Willi syndrome: a randomized, double-blind, controlled crossover trial. Clin Endocrinol. 2016; 85(6):979–987. DOI: 10.1111/cen.13169. PMID: 27486141.

68. Miller JL, Tamura R, Butler MG, Kimonis V, Sulsona C, Gold JA, et al. Oxytocin treatment in children with Prader–Willi syndrome: a double-blind, placebo-controlled, crossover study. Am J Med Genet A. 2017; 173(5):1243–1250. DOI: 10.1002/ajmg.a.38160. PMID: 28371242. PMCID: PMC5828021.

69. Tauber M, Boulanouar K, Diene G, Çabal-Berthoumieu S, Ehlinger V, Fichaux-Bourin P, et al. The use of oxytocin to improve feeding and social skills in infants with Prader-Willi syndrome. Pediatrics. 2017; 139(2):e20162976. DOI: 10.1542/peds.2016-2976. PMID: 28100688.

70. Damen L, Grootjen LN, Juriaans AF, Donze SH, Martin Huisman T, Visser JA, et al. Oxytocin in young children with Prader-Willi syndrome: results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin. Clin Endocrinol. 2021; 94(5):774–785. DOI: 10.1111/cen.14387. PMID: 33296519. PMCID: PMC8246775.

71. Hollander E, Levine KG, Ferretti CJ, Freeman K, Doernberg E, Desilva N, et al. Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi syndrome: a randomized controlled pilot trial. J Psychiatr Res. 2021; 137:643–651. DOI: 10.1016/j.jpsychires.2020.11.006. PMID: 33190843.

72. Butler MG, Hartin SN, Hossain WA, Manzardo AM, Kimonis V, Dykens E, et al. Molecular genetic classification in Prader-Willi syndrome: a multisite cohort study. J Med Genet. 2019; 56(3):149–153. DOI: 10.1136/jmedgenet-2018-105301. PMID: 29730598. PMCID: PMC7387113.

73. McCandless SE, Yanovski JA, Miller J, Fu C, Bird LM, Salehi P, et al. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader–Willi syndrome: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017; 19(12):1751–1761. DOI: 10.1111/dom.13021. PMID: 28556449. PMCID: PMC5673540.